ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
22 announcements
Syncom Formulations' promoters have voluntarily waived their right to the proposed final dividend of ₹0.10 per share. This waiver reduces total dividend payout obligations.
Syncom Formulations fixed 23 Sep 2026 as record date for a proposed 10% dividend (Rs.0.10/share) pending AGM approval. The 38th AGM is scheduled for 30 Sep 2026.
Syncom Formulations (India) Limited informed exchanges about the dispatch of letters to shareholders with unregistered email addresses, providing instructions to access the 38th AGM Notice and Annual Report.
Syncom Formulations (India) Limited issued notice for its 38th Annual General Meeting, scheduled for 30th September 2026 via Video Conferencing.
Syncom Formulations (India) Limited has filed its 38th Annual Report for the financial year 2025-26, which includes the Notice for the upcoming Annual General Meeting.
Syncom Formulations reported strong Q1 FY27 performance, with revenue rising to ₹125.53 crore and profit after tax reaching ₹24.85 crore. The board recommended a final dividend.
Syncom Formulations (India) Limited announced remote e-voting details for its upcoming 38th Annual General Meeting scheduled for September 30, 2026.
Syncom Formulations appointed M/s M. Goyal & Co. as Cost Auditor and M/s Bansal & Agrawal as Internal Auditor for FY 2026-27.
Syncom Formulation (India) Ltd reported revenue from operations of ₹125.5 Cr (+7.4% YoY) and net profit of ₹24.8 Cr (+57.0% YoY) for Q1 FY27.
Syncom Formulations (India) Limited declared a record date of 23rd September 2026 for the final dividend of Rs. 0.10 per share. The 38th AGM is scheduled for 30th September 2026.
Syncom Formulations approved the financial results for the quarter ended June 30, 2026, declared management changes, and recommended a final dividend of Rs. 0.10 per share.
Syncom Formulations (India) Ltd announced the resignation of Mr. Kedarmal Shankarlal Bankda as Whole-Time Director and Director, effective August 11, 2026.
Syncom Formulations (India) Limited will hold a board meeting on August 11, 2026, to consider quarterly financial results and dividend recommendations.
Syncom Formulations India Ltd has filed its quarterly shareholding pattern for the period ended June 30, 2026, in compliance with SEBI regulations.
Syncom Formulation (India) Ltd reported revenue from operations of ₹135.4 Cr (-9.1% YoY) and net profit of ₹25.2 Cr (+42.4% YoY) for Q4 FY26.
Syncom Formulations (India) Limited reported audited consolidated net profit of ₹76.44 Crore for FY2026. The board approved results showing significant annual revenue growth to ₹520.51 Crore.
Syncom Formulations (India) Limited submitted its Annual Secretarial Compliance Report for the financial year ended March 31, 2026. The report confirms overall regulatory adherence.
Syncom Formulations (India) will hold a board meeting on May 22, 2026. Directors will consider and approve the audited financial results for March 2026.
Syncom Formulations (India) Limited has completed the acquisition of a commercial property in Mumbai from HDFC Bank Ltd for ₹57.26 Crore. The purchase involves the entire 7th Floor of Trade Star, Andheri-Kurla Road. This material acquisition was funded as a full and final consideration for the asset.
Syncom Formulations (India) Ltd submitted its compliance certificate under Regulation 74(5) of SEBI Regulations for the quarter ended March 31, 2026. The certificate confirms that security certificates received for dematerialization were processed, mutilated, and cancelled as per regulatory requirements by their Registrar, Ankit Consultancy Pvt. Ltd.
Promoters of Syncom Formulations (India) Limited, including Kedarmal and Vijay Shankarlal Bankda, submitted their annual declaration under SEBI SAST Regulations for FY 2025-26. They confirmed no new encumbrances were made on their shareholding during the year, maintaining transparency in promoter-level security interests.
Syncom Formulations (India) Ltd confirmed it does not meet the SEBI criteria for 'Large Corporate' status for the financial year ended March 31, 2026. The company reported zero outstanding borrowings in its initial disclosure, making the mandatory debt market borrowing framework non-applicable.